Chronic Rhinosinusitis Trial, Completed NCT00924404 Sponsor: University of Iowa Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial enrolled 53 adults in total — 27 in a group using xylitol nasal rinses and 26 in a group using saline (salt water) nasal rinses. By the end of the study, 21 people in the xylitol group and 22 in the saline group had completed it. The trial was measuring nose and sinus-related quality of life using a 20-question survey called the SNOT-20, where a score of 0 means no symptoms and 100 means symptoms are "as troublesome as possible." It also tracked how many courses of antibiotics participants needed during the study period. The reported data shows that at 12 weeks, the average SNOT-20 score for the xylitol group was 7 out of 100, and for the saline group it was 11 out of 100 — both sitting in what the scale describes as the mild symptom range (0–30). For antibiotic use, the reported data shows the xylitol group took an average of 1.90 courses of antibiotics during the study, compared with 1.77 courses in the saline group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Chronic Rhinosinusitis Trial, Completed

NCT00924404
Completed Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Group 1 (People with a healthy immune system and chronic sinus problems):

  • You are 18 years of age or older
  • You have been experiencing chronic rhinosinusitis (long-term sinus problems) for 12 weeks or more, even after receiving medical treatment
  • You have at least 2 of these symptoms: thick nasal discharge (from the front or back of the nose), blocked nose, pain/pressure/fullness in the face, or reduced sense of smell
  • A CT scan or camera examination of your nose has confirmed sinus inflammation

Group 2 (People with chronic sinus problems AND an antibody deficiency):

  • You are 18 years of age or older
  • You have been experiencing chronic rhinosinusitis (long-term sinus problems) for 12 weeks or more, even after receiving medical treatment
  • You have at least 2 of these symptoms: thick nasal discharge, blocked nose, facial pain/pressure/fullness, or reduced sense of smell
  • A CT scan or camera examination of your nose has confirmed sinus inflammation

Who may not be able to join:

Group 1 exclusions:

  • You have cystic fibrosis
  • You have a fungal sinus infection
  • Your immune system is weakened (for example, due to long-term steroid use of more than 30 days, HIV/AIDS, active cancer, or current chemotherapy)
  • You have a known condition affecting the tiny hair-like structures in your airways (confirm with trial site)
  • You have a tumor in your nose or sinuses
  • You are pregnant

Group 2 exclusions:

  • You have cystic fibrosis
  • You have a tumor in your nose or sinuses
  • You are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Completed
Phase
Not Applicable
Sponsor
University of Iowa
Registry
ClinicalTrials.gov
Start date
1 May 2009
Est. completion
1 August 2014

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

SNOT-20 Scores at 12 Weeks

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov